|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_001373, 42794009|
|Calculated MW||46090 Da|
|Application Notes||DPAGT1 antibody can be used for detection of DPAGT1 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Target/Specificity||DPAGT1; At least four isoforms of DPAGT1 are known to exist; this antibody will recognize the two longest isoforms. DPAGT1 antibody is predicted to not cross-react with UHRF1BP1.|
|Reconstitution & Storage||DPAGT1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||DPAGT1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the initial step of dolichol-linked oligosaccharide biosynthesis in N-linked protein glycosylation pathway: transfers GlcNAc-1-P from UDP-GlcNAc onto the carrier lipid dolichyl phosphate (P-dolichol), yielding GlcNAc-P-P- dolichol.|
|Cellular Location||Endoplasmic reticulum membrane; Multi-pass membrane protein|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DPAGT1 Antibody: The UDP-N-acetylglucosamine-dolichyl-phosphate N-acetyl-glucosaminephosphotransferase (DPAGT1) is an enzyme that catalyzes the first step in the dolichol-linked oligosaccharide pathway for glycoprotein biosynthesis. Mutations in this integral endoplasmic reticulum (ER) membrane protein enzyme belongs to the glycosyltransferase family 4 results in the congenital disorder of glycosylation type Ij with symptoms such as severe hypotonia, medically intractable seizures, mental retardation, microcephaly, and exotropia. Recent experiments have shown that DPAGT1 is a target of the Wnt/beta-catenin signaling pathway, with Wnt3a inducing higher DPAGT1 mRNA expression.
Wu X, Rush JS, Karaoglu D, et al. Deficiency of UDP-GlcNAc:Dolichol Phosphate N-Acetylglucosamine-1 Phosphate Transferase (DPAGT1) causes a novel congenital disorder of glycosylation type Ij. Hum. Mutat. 2003; 22:144-50.
Bretthauer RK. Structure, expression, and regulation of UDP-GlcNAc:dolichol phosphate GlcNAc-1-phosphate transferase (DPAGT1). Curr. Drug Targets 2009; 10:477-82
Sengupta PK, Bouchie MP, and Kukuruzinska MA. N-glycosylation gene DPAGT1 is a target of the Wnt/beta-catenin signaling pathway. J. Biol. Chem. 2010; 285:31164-73.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.